Direct Impact

Concepts for which Eli Lilly Australia has direct influence:

intravesical gemcitabine
small intestinal
rate infusion
cognitive remediation
tract carcinomas
peptide-1 analogue
operable biliary

Prominent publications by Eli Lilly Australia

KOL-Index: 2 Glucagon-like peptide-1 (GLP-1) is a naturally occurring hormone in the human body that has the effect of stimulating insulin secretion and slowing stomach emptying, helping to limit the rise in blood glucose after a meal. Exenetide is a drug that mimics GLP-1, and has recently been approved in Australia for the treatment of diabetes. However, there is little information on how GLP-1 can ...
Known for
Glucose Absorption
KOL-Index: 2 The treatment for recurrent bladder tumour following trans-urethral resection (TUR) continues to be problematic. This protocol is a phase ll trial of gemcitabine directly instilled into the bladder of patients with transitional cell carcinoma who have undergone a standard TUR. The objectives of the study are to determine if intravesical gemcitabine is capable of reducing the rate of tumour ...
Known for
Intravesical Bcg | Tumour Trans | Recurrent Bladder | Protocol Phase

© 2022 - Key Opinion Leaders -
Key Opinion Leaders, LLC ,
2025 NW 102 Avenue, Suite 111 Doral , FL   33172